Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 210Triple Negative Breast Neoplasms 32Stomach Neoplasms 30Inflammatory Breast Neoplasms 21Esophageal Neoplasms 15Carcinoma, Hepatocellular 15Lymphoma, Large B-Cell, Diffuse 9Sarcoma 8Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Urinary Bladder Neoplasms 5Breast Neoplasms, Male 5Adenocarcinoma Of Esophagus 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma 4Liver Neoplasms 4Testicular Neoplasms 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Hemangiosarcoma 3Carcinoma, Ductal, Breast 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplastic Cells, Circulating 2Neoplasms, Germ Cell and Embryonal 2

Interventions

palbociclib 1Letrozole 1Fulvestrant 1Epirubicin 1Docetaxel 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hormone Receptor Positive HER-2 Negative Breast Cancer × Epirubicin × Clear all
NCT05901428 2023-06-15

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Fudan University

Phase 3 Recruiting
1,736 enrolled
Breast

Hormone Receptor Positive HER-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡